China’s AI Models Put to the Test in the Clinic: A Reality Check for Ocular Diagnostics

Chinese scientists have conducted one of the first systematic evaluations of multimodal large language models (M-LLMs) for diagnosing ocular surface diseases (OSDs) in a real-world clinical setting. Using a retrospective dataset of 259 representative cases from Aksu, China, the researchers put five leading M-LLMs—including GPT-5, Gemini-2.5 Pro, GLM-4.5V, and Claude-Sonnet-4.5—through their paces. The models were tasked with processing anterior segment photographs alongside structured clinical data to produce accurate diagnoses, testing their mettle in a resource-limited region where diagnostic access remains scarce.

Beyond raw accuracy, the study assessed safety and equity, two critical dimensions often overlooked in benchmark-centric AI research. The findings reveal a nuanced picture: while these models hold clear potential to support clinicians in underserved areas, significant gaps remain in diagnostic reliability and fairness across patient populations. The work underscores that while China leads in deploying advanced AI architectures, translating that lead into safe, equitable clinical practice is still a formidable challenge. The full findings are set for publication in the American Journal of Pathology.

Why it matters:
As China accelerates its ambition to become a global leader in AI-powered healthcare, real-world accuracy and equity are not just ethical requirements—they are commercial prerequisites. Investors and health-tech firms eyeing the Chinese diagnostic market should note that regulatory and clinical adoption pathways will increasingly demand evidence that goes beyond lab benchmarks. This study provides a concrete framework for evaluating what works, where AI falls short, and how deployment strategies must adapt to local clinical realities.

Source →